No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Lakewood-Amedex Biotherapeutics, Inc. (LABT) stock was $0.84 as of Oct 6, 2026, 9:58 AM EDT, down 1.74% from the previous close.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Biotechnology · University Park, FL
LATEST PRICE
$0.84
52-WEEK RANGE
$0.82 - $98.20
BETA
-4.76
% FROM 52W HIGH
-99.14%
MARKET CAP
$1.47M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
0.34
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.02
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
N/A
3Y TOTAL RETURN
annualized (CAGR)
N/A
5Y TOTAL RETURN
annualized (CAGR)
N/A
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.75
vs Estimate
$-0.65
Revenue
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$12.00
+1328.6% upside
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.81 | $-0.81 | $-0.81 | 1 |
| Quarter ending Dec 2026 | $-0.76 | $-0.76 | $-0.76 | 1 |
Annual
| Period | Low | Avg | High |
|---|
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LABT | $1.47M | $0.84 | -1.74% | N/A | N/A | N/A | N/A |
| 2IVF | $1.47M | $0.82 | -0.74% | -97.33% | -90.41% | -69.30% | vs LABT |
| 3CRIS | $1.48M | $0.76 | -3.98% | -97.57% | -81.06% | -59.09% | vs LABT |
| 4ELAB | $1.44M | $3.18 | -2.75% | -99.94% | N/A | N/A | vs LABT |
| 5ARTL | $1.38M | $3.57 | +1.71% | -91.59% | -64.27% | N/A | vs LABT |
| 6GNPX | $1.32M | $2.62 | -3.68% | -98.68% | -88.16% | N/A | vs LABT |
Low
$12.00
Current
$0.84
High
$12.00
| # Analysts |
|---|
| FY 2026 | $4.96 | $4.96 | $4.96 | 1 |
| FY 2027 | $1.32 | $1.32 | $1.32 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
